| Literature DB >> 22619603 |
Tiago Gomes Fernandes1, Amanda Rafaela Carneiro de Mesquita, Karina Perrelli Randau, Adelisa Alves Franchitti, Eulália Azevedo Ximenes.
Abstract
The aim of this study was to evaluate the antimicrobial activity of aqueous extract of Psidium guineense Swartz (Araçá-do-campo) and five antimicrobials (ampicillin, amoxicillin/clavulanic acid, cefoxitin, ciprofloxacin, and meropenem) against twelve strains of Staphylococcus aureus with a resistant phenotype previously determined by the disk diffusion method. Four S. aureus strains showed resistance to all antimicrobial agents tested and were selected for the study of the interaction between aqueous extract of P. guineense and antimicrobial agents, by the checkerboard method. The criteria used to evaluate the synergistic activity were defined by the fractional inhibitory concentration index (FICI). All S. aureus strains were susceptible to P. guineense as determined by the microdilution method. The combination of the P. guineense extract with the antimicrobial agents resulted in an eight-fold reduction in the MIC of these agents, which showed a FICI ranging from 0.125 to 0.5, suggesting a synergistic interaction against methicillin-resistant Staphylococcus aureus (MRSA) strains. The combination of the aqueous extract of P. guineense with cefoxitin showed the lowest FICI values. This study demonstrated that the aqueous extract of P. guineense combined with beta lactamics antimicrobials, fluoroquinolones, and carbapenems, acts synergistically by inhibiting MRSA strains.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22619603 PMCID: PMC3349319 DOI: 10.1100/2012/158237
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
MIC/MBC of the aqueous extract of Psidium guineense and antimicrobial agents against MRSA strains.
|
| MIC/MBC ( | |||||||
|---|---|---|---|---|---|---|---|---|
| AMC | AMP | CEF | CIP | GET | MER | AE | Resistance phenotype1 | |
| ATCC 25923 | 3.12/6.24 | 3.12/6.24 | 3.12/6.24 | 3.12/6.24 | 0.39/0.78 | 3.12/6.24 | 250/500 | Control strain |
| LFBM 01 | 25.0/50.0 | 400/800 | 400/800 | 50.0/100 | 12.5/25.0 | 25.0/50.0 | 250/500 | AMC, CFO, CIP, GET |
| LFBM 05 | 6.25/12.5 | 100/200 | 25/50.0 | 3.12/6.24 | 3.12/6.24 | 12.5/25.0 | 250/500 | AMP, AZI, CFO, PEN |
| LFBM 08 | 3.12/6.24 | 100/200 | 12.5/25.0 | 3.12/6.24 | 3.12/6.24 | 6.25/12.5 | 250/500 | AMP; AZI, CIP, CFO |
| LFBM 16 | 12.5/25.0 | 25.0/50.0 | 12.5/25.0 | 3.12/6.24 | 3.12/6.24 | 6.25/12.5 | 250/500 | AMP, AZI, CFO, PEN |
| LFBM 26 | 50.0/100 | 400/800 | 400/800 | 50.0/100 | 25.0/50.0 | 25.0/50.0 | 250/500 | AMC, AMP, CFO, CIP |
| LFBM 28 | 25.0/50.0 | 400/800 | 100/200 | 50.0/100 | 25.0/50.0 | 12.5/25.0 | 250/500 | AMC, CIP, CFO, GET |
| LFBM 29 | 12.5/25.0 | 50.0/100 | 25/50.0 | 3.12/6.24 | 3.12/6.24 | 12.5/25.0 | 500/1000 | AMC, AMP, CFO, PEN |
| LFBM 30 | 12.5/25.0 | 200/400 | 12.5/25.0 | 50.0/100 | 3.12/6.24 | 12.5/25.0 | 250/500 | AMC, AMP, CFO, CIP |
| LFBM 31 | 12.5/25.0 | 100/100 | 12.5/25.0 | 50.0/100 | 3.12/6.24 | 6.25/12.5 | 250/500 | AMP, AZI, CFO; CIP; |
| LFBM 32 | 12.5/25.0 | 200/200 | 12.5/25.0 | 50.0/100 | 3.12/6.24 | 12.5/25.0 | 250/500 | AMP, CFO, CIP, PEN |
| LFBM 33 | 12.5/25.0 | 200/200 | 200/200 | 50.0/100 | 3.12/6.24 | 12.5/25.0 | 250/500 | AMC, AMP, CFO, CIP |
MIC: minimal inhibitory concentration; MBC: minimal bactericidal concentration; ATCC: American Type Culture Collection; LFBM: Laboratório de Fisiologia e Bioquímica de Microorganismos; AMC: amoxicillin/clavulanic acid; AMP: ampicillin; AZI: azithromycin; CFO: cefoxitin; CIP: ciprofloxacin; GET: gentamicin; PEN: penicillin; MER: meropenem; AE: aqueous extract of P. guineense.
1Resistance phenotype determined by the disk-diffusion method.
Combination testing of the aqueous extract of Psidium guineense with antimicrobial agents against MRSA strains.
|
| Combination | Individual MIC ( | Combination MIC ( | Individual FIC | FIC index (FICI) | Interpretation | % MIC reduced | % reduction of viable cells1 |
|---|---|---|---|---|---|---|---|---|
| LFBM 01 | AE + AMC | 250/25 | 125/0.048 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 80.21 |
| AE + AMP | 250/400 | 125/0.78 | 0,5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 84.43 | |
| AE + CFO | 250/400 | 125/0.78 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 87.04 | |
| AE + CIP | 250/50 | 125/0.09 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 93.49 | |
| AE + MER | 250/25 | 125/0.048 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 84.24 | |
|
| ||||||||
| LFBM 26 | AE + AMC | 250/50.0 | 125/0.78 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 88.82 |
| AE + AMP | 250/400 | 125/0.78 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 83.58 | |
| AE + CFO | 250/400 | 31.25/0.78 | 0.125/0.002 | 0.125 | Synergistic | 87.5/99.8 | 80.90 | |
| AE + CIP | 250/50.0 | 125/0.09 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 94.59 | |
| AE + MER | 250/25 | 125/0.048 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 80.76 | |
|
| ||||||||
| LFBM 28 | AE + AMC | 250/12.5 | 125/0.024 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 83.38 |
| AE + AMP | 250/400 | 125/0.78 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 89.71 | |
| AE + CFO | 250/100 | 125/0.19 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 86.91 | |
| AE + CIP | 250/50.0 | 125/0.09 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 94.45 | |
| AE + MER | 250/25.0 | 62.5/0.048 | 0.25/0.002 | 0.25 | Synergistic | 75.0/99.8 | 89.08 | |
|
| ||||||||
| LFBM 33 | AE + AMC | 250/12.5 | 125/0.024 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 78.89 |
| AE + AMP | 250/200 | 125/0.39 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 76.72 | |
| AE + CFO | 250/200 | 62.5/0.39 | 0.25/0.002 | 0.25 | Synergistic | 75.0/99.8 | 81.53 | |
| AE + CIP | 250/50.0 | 62.5/0.78 | 0.25/0.002 | 0.25 | Synergistic | 75.0/99.8 | 94.09 | |
| AE + MER | 250/12.5 | 125/0.024 | 0.5/0.002 | 0.5 | Synergistic | 50.0/99.8 | 81.84 | |
MIC: minimal inhibitory concentration; FIC: fractional inhibitory concentration; AMC: amoxicillin/clavulanic acid; AMP: ampicillin; CFO: cefoxitin; CIP: ciprofloxacin; MER: meropenem; AE: aqueous extract of P. guineense; LFBM: Laboratório de Fisiologia e Bioquímica de Microorganismos.
% of MIC reduced = (MICalone − MICcombined) × 100/MICalone.
1%reduction of viable cells in wells containing the combination aqueous extract of P. guineense (1/2 MIC) and antimicrobials agents (1/512 MIC).